Clinical Trial Update: Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008) [Phase 3]

View source ↗

Summary

Phase 3 trial on MK-3641 (RAGWITEK) in children with ragweed-induced rhinoconjunctivitis with or without asthma completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Rhinoconjunctivitis Seasonal

Drugs mentioned

• Ragwitek (ragweed pollen extract sublingual tablet)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Rhinitis, Allergic, Seasonal | Phase 3 | Status: COMPLETED | Results posted: 2019-07-09